Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.

Abstract

Since regional drug administration enables to maintain a high drug concentration within tumors, we compared the plasma concentration and biodistribution of doxorubicin (Dox) from drug-loaded conventional liposomes by local or systemic administration. The results demonstrated that drug concentration was substantially improved in liver as well as a decrease in blood and other organs by spleen injection mimicking portal vein perfusion (regional administration). To further investigate the targeted therapeutic effect of galactosylated liposome encapsulated doxorubicin (Dox) by regional administration, liver targeting liposomes were prepared by incorporating galactosylated-DPPE to conventional liposomes. Liposome uptake and targeting were verified in vitro and in vivo by fluorescence microscopy and xenogen IVIS imaging system, respectively. The results showed that galactose targeted liposomes presented a stronger specific cell uptake by human hepatocellular carcinoma HepG2 cells compared to the non-targeted liposomes. In vivo fluorescence imaging showed that the intra-hepatic deposition of conventional and galactosylated liposomes via spleen injection was more than that via tail vein administration, and galactosylated liposomes had higher fluorescent intensity over conventional liposomes in the liver post spleen administration. The anti-tumor effect of various drug administration routes for both liposomal formulations was evaluated using a murine liver metastasis model of colon cancer. The results indicated that tumor progression in the liver and mesenteric lymph nodes was significantly suppressed by Dox-loaded galactosylated liposomes via spleen injection, while no significance was observed in non-targeted formulations. Our data indicated that local perfusion of galactosylated liposomal doxorubicin had a great promise for the treatment of liver metastasis from colon cancer.

• Authors: Chen Zhao, Qiang Feng, Zengpei Dou, Wei Yuan, Chenguang Sui, Xinghua Zhang, Guimin Xia, Hongfang Sun, Jie Ma
• Journal: PloS one (PLoS One) Vol. 8 Issue 9 Pg. e73860 ( 2013) ISSN: 1932-6203 [Electronic] United States
• PMID: 24040096 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Asialoglycoprotein Receptor
• liposomal doxorubicin
• Polyethylene Glycols
• Doxorubicin

Topics

• Animals
• Antibiotics, Antineoplastic (administration & dosage, chemistry, metabolism, pharmacokinetics)
• Asialoglycoprotein Receptor (metabolism)
• Cell Line, Tumor
• Colonic Neoplasms (drug therapy, metabolism, pathology)
• Disease Models, Animal
• Doxorubicin (administration & dosage, analogs & derivatives, chemistry, metabolism, pharmacokinetics)
• Female
• Humans
• Liver Neoplasms (drug therapy, metabolism, secondary)
• Mice
• Polyethylene Glycols (administration & dosage, chemistry, metabolism, pharmacokinetics)
• Tissue Distribution
• Xenograft Model Antitumor Assays